Coagulation testing in 11 patients at baseline, day 1 and day 120 post-TAVI
| Coagulation markers | A. Pre-TAVI | B. day 1 post-TAVI | C. day 120 post-TAVI | P value A vs B | P value A vs C |
| Haemoglobin (120–150 g/L) | 118±21.5 | 112±18.2 | 127±16.4 | 0.082 | 0.330 |
| Platelets (150–400×109/L) | 199±54.9 | 169±52.2 | 227±93.6 | 0.009* | 0.406 |
| White cell count (4–10×109/L) | 7.1±1.6 | 10.0±3.3 | 7.9±2.0 | 0.003* | 0.315 |
| LDH (135–214 U/L) | 224±18 | 232±13 | 243±31 | 0.232 | 0.015* |
| PF 1+2 (69–229 ng/mL) | 791±632 | 451±11.1 | 401±11.1 | 0.453 | 0.352 |
| TAT (1.0–4.1 ng/mL) | 56±63 | 8.1±2.9 | 3.9±0.3 | 0.332 | 0.124 |
| Fibrinogen (1.7–3.9 s) | 3.6±0.8 | 3.8±0.8 | 4.3±0.9 | – | 0.110 |
| D-Dimer (0–0.55 ng/mL) | 0.49±0.27 | 1.86±0.79 | 0.87±0.47 | 0.046* | 0.465 |
| APTT (0.8–1.2 ratio) | 0.96±0.05 | 0.96±0.05 | 0.90±0.00 | – | 0.465 |
This table demonstrates a random sample of 11 patients who attended for TAVI. This demonstrates that a baseline derangement in clotting exists in all patients with aortic stenosis, this is further exacerbated by the procedure, and tends to settle at day 120 following valve endothelialisation. Reference ranges are provided in brackets. Data are presented as mean±SD.
*P<0.05 (statistical significance)
LDH, lactate dehydrogenase; PF 1+2, prothrombin factors 1+2; TAT, thrombin antithrombin; TAVI, transcatheter aortic valve implantation.